HORIZON-BREAST06
What it tests: Trastuzumab rezetecan (SHR-A1811) in HER2-low advanced breast cancer. Randomized phase 3 study.
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.